Identification

Name
Levofloxacin
Accession Number
DB01137  (APRD00477, DB06085)
Type
Small Molecule
Groups
Approved, Investigational
Description

A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. [PubChem]

Structure
Thumb
Synonyms
  • (-)-Ofloxacin
  • (3S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid
  • (S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
  • (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
  • (S)-Ofloxacin
  • L-ofloxacin
  • Levofloxacine
  • Levofloxacino
  • Levofloxacinum
  • Ofloxacin S-(-)-form
External IDs
MP-376
Product Ingredients
IngredientUNIICASInChI Key
Levofloxacin hemihydrate6GNT3Y5LMF138199-71-0SUIQUYDRLGGZOL-RCWTXCDDSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act LevofloxacinTablet500 mgOralTeva2009-06-24Not applicableCanada
Act LevofloxacinTablet750 mgOralTeva2009-06-24Not applicableCanada
Act LevofloxacinTablet250 mgOralTeva2009-06-24Not applicableCanada
Auro-levofloxacinTablet250 mgOralAuro Pharma Inc2016-04-12Not applicableCanada
Auro-levofloxacinTablet500 mgOralAuro Pharma Inc2016-04-12Not applicableCanada
Auro-levofloxacinTablet750 mgOralAuro Pharma Inc2016-04-12Not applicableCanada
Ava-levofloxacinTablet250 mgOralAvanstra Inc2011-09-152014-08-21Canada
Ava-levofloxacinTablet500 mgOralAvanstra Inc2011-09-152014-08-21Canada
Dom-levofloxacinTablet500 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-levofloxacinTablet750 mgOralDominion PharmacalNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-levofloxacinTablet500 mgOralApotex Corporation2009-06-24Not applicableCanada
Apo-levofloxacinTablet750 mgOralApotex Corporation2009-06-24Not applicableCanada
Apo-levofloxacinTablet250 mgOralApotex Corporation2009-06-24Not applicableCanada
LevaquinTablet250 mg/1OralDirectrx2016-05-26Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralPreferreed Pharmaceuticals Inc.2011-08-12Not applicableUs
LevofloxacinTablet750 mg/1OralCardinal Health2011-06-23Not applicableUs
LevofloxacinInjection, solution5 mg/mLIntravenousClaris Lifesciences, Inc.2013-07-01Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralUnit Dose Services2012-11-10Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralTeva2011-06-202016-05-31Us
LevofloxacinTablet, film coated250 mg/1OralAurobindo Pharma2011-06-20Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LevofloxacinTablet, film coated750 mg/1OralPreferreed Pharmaceuticals Inc.2017-11-01Not applicableUs
International/Other Brands
Cravit / Elequine / Floxel / Leroxacin / Levokacin / Levox / Levoxacin / Mosardal / Nofaxin / Reskuin / Tavanic
Categories
UNII
RIX4E89Y14
CAS number
100986-85-4
Weight
Average: 361.3675
Monoisotopic: 361.143784348
Chemical Formula
C18H20FN3O4
InChI Key
GSDSWSVVBLHKDQ-JTQLQIEISA-N
InChI
InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1
IUPAC Name
(2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0⁵,¹³]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
SMILES
C[[email protected]]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1

Pharmacology

Indication

For the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species, Staphylococus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus (Groups C/F/G), Viridans group streptococci, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.

Structured Indications
Pharmacodynamics

Levofloxacin, a fluoroquinolone antiinfective, is the optically active L-isomer of ofloxacin. Levofloxacin is used to treat bacterial conjunctivitis, sinusitis, chronic bronchitis, community-acquired pneumonia and pneumonia caused by penicillin-resistant strains of Streptococcus pneumoniae, skin and skin structure infections, complicated urinary tract infections and acute pyelonephritis.

Mechanism of action

Levofloxacin inhibits bacterial type II topoisomerases, topoisomerase IV and DNA gyrase. Levofloxacin, like other fluoroquinolones, inhibits the A subunits of DNA gyrase, two subunits encoded by the gyrA gene. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing; DNA replication and transcription is inhibited.

TargetActionsOrganism
ADNA gyrase subunit A
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
ADNA topoisomerase 4 subunit A
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
ADNA topoisomerase 2-alpha
inhibitor
Human
Absorption

Absorption of ofloxacin after single or multiple doses of 200 to 400 mg is predictable, and the amount of drug absorbed increases proportionately with the dose.

Volume of distribution
Not Available
Protein binding

24-38% (to plasma proteins)

Metabolism

Mainly excreted as unchanged drug (87%); undergoes limited metabolism in humans.

Route of elimination

Mainly excreted as unchanged drug in the urine.

Half life

6-8 hours

Clearance
Not Available
Toxicity

Side effects include disorientation, dizziness, drowsiness, hot and cold flashes, nausea, slurring of speech, swelling and numbness in the face

Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Levofloxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Levofloxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Levofloxacin.Experimental, Illicit
AcarboseLevofloxacin may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Levofloxacin.Approved
AceclofenacAceclofenac may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
AcemetacinAcemetacin may increase the neuroexcitatory activities of Levofloxacin.Approved
AcenocoumarolLevofloxacin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Levofloxacin can be increased when it is combined with Acetaminophen.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Levofloxacin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Levofloxacin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Levofloxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Levofloxacin.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Levofloxacin.Approved
AlbendazoleThe serum concentration of Levofloxacin can be increased when it is combined with Albendazole.Approved, Vet Approved
AlbiglutideLevofloxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlclofenacAlclofenac may increase the neuroexcitatory activities of Levofloxacin.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Levofloxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Levofloxacin.Experimental, Investigational
AlectinibThe serum concentration of Levofloxacin can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Levofloxacin can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
AlgeldrateAlgeldrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Levofloxacin.Approved, Investigational
AlmagateAlmagate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlmasilateAlmasilate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlminoprofenAlminoprofen may increase the neuroexcitatory activities of Levofloxacin.Experimental
AlogliptinLevofloxacin may increase the hypoglycemic activities of Alogliptin.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AluminiumAluminium can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmantadineAmantadine may increase the QTc-prolonging activities of Levofloxacin.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Levofloxacin.Approved, Investigational
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Levofloxacin.Experimental, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Levofloxacin.Approved
Aminohippuric acidThe serum concentration of Levofloxacin can be increased when it is combined with Aminohippuric acid.Approved, Investigational
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Levofloxacin.Approved
AmiodaroneThe serum concentration of Levofloxacin can be decreased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Levofloxacin.Approved
AmlodipineThe serum concentration of Levofloxacin can be increased when it is combined with Amlodipine.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Levofloxacin.Approved
AmprenavirThe serum concentration of Levofloxacin can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Levofloxacin can be increased when it is combined with Amsacrine.Approved
AnagrelideLevofloxacin may increase the QTc-prolonging activities of Anagrelide.Approved
AndrographolideAndrographolide may increase the neuroexcitatory activities of Levofloxacin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Levofloxacin.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Levofloxacin.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Levofloxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Levofloxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Levofloxacin.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Levofloxacin.Approved
ApocyninApocynin may increase the neuroexcitatory activities of Levofloxacin.Investigational
ApomorphineApomorphine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Levofloxacin.Approved, Investigational
ArtemetherLevofloxacin may increase the QTc-prolonging activities of Artemether.Approved
AsenapineLevofloxacin may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe serum concentration of Levofloxacin can be increased when it is combined with Astemizole.Approved, Withdrawn
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Levofloxacin.Investigational
AtazanavirAtazanavir may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
AtenololThe serum concentration of Levofloxacin can be increased when it is combined with Atenolol.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Levofloxacin.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Levofloxacin is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Levofloxacin.Approved, Investigational
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Levofloxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Levofloxacin.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Levofloxacin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Levofloxacin.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Levofloxacin.Approved, Investigational
BedaquilineLevofloxacin may increase the QTc-prolonging activities of Bedaquiline.Approved
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Levofloxacin.Approved, Investigational
BendazacBendazac may increase the neuroexcitatory activities of Levofloxacin.Experimental
BenorilateBenorilate may increase the neuroexcitatory activities of Levofloxacin.Experimental
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Levofloxacin.Withdrawn
BenzocaineThe serum concentration of Levofloxacin can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Levofloxacin can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Levofloxacin.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Levofloxacin.Approved, Investigational
BevoniumBevonium may increase the neuroexcitatory activities of Levofloxacin.Experimental
BiperidenThe serum concentration of Levofloxacin can be increased when it is combined with Biperiden.Approved, Investigational
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Levofloxacin.Approved, Withdrawn
BortezomibBortezomib may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Levofloxacin.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Levofloxacin.Approved
BromfenacBromfenac may increase the neuroexcitatory activities of Levofloxacin.Approved
BromocriptineThe serum concentration of Levofloxacin can be increased when it is combined with Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the neuroexcitatory activities of Levofloxacin.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Levofloxacin.Approved
BufexamacBufexamac may increase the neuroexcitatory activities of Levofloxacin.Experimental
BumadizoneBumadizone may increase the neuroexcitatory activities of Levofloxacin.Experimental
BuprenorphineThe serum concentration of Levofloxacin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Levofloxacin.Approved
BuspironeThe serum concentration of Levofloxacin can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Levofloxacin.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Levofloxacin.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Levofloxacin.Approved
CalciumCalcium can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CitrateCalcium Citrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Calcium lactateCalcium lactate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateCalcium lactate gluconate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium laevulateCalcium laevulate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium pangamateCalcium pangamate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium PhosphateCalcium Phosphate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Levofloxacin.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Levofloxacin.Approved
Candesartan cilexetilThe serum concentration of Levofloxacin can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Levofloxacin can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Levofloxacin can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the neuroexcitatory activities of Levofloxacin.Experimental, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Levofloxacin.Approved
CarprofenCarprofen may increase the neuroexcitatory activities of Levofloxacin.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Levofloxacin can be increased when it is combined with Carvedilol.Approved, Investigational
CaseinCasein can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CaspofunginThe serum concentration of Levofloxacin can be increased when it is combined with Caspofungin.Approved
CastanospermineCastanospermine may increase the neuroexcitatory activities of Levofloxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
CeritinibLevofloxacin may increase the QTc-prolonging activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Levofloxacin.Withdrawn
ChloroquineChloroquine may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
ChlorpropamideThe serum concentration of Levofloxacin can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Levofloxacin can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
CholesterolThe serum concentration of Levofloxacin can be increased when it is combined with Cholesterol.Experimental, Investigational
Cholic AcidThe serum concentration of Levofloxacin can be decreased when it is combined with Cholic Acid.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the neuroexcitatory activities of Levofloxacin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Levofloxacin.Approved, Investigational
CilazaprilThe serum concentration of Levofloxacin can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Levofloxacin can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
CisaprideLevofloxacin may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Levofloxacin.Approved
CitalopramThe serum concentration of Levofloxacin can be increased when it is combined with Citalopram.Approved
ClarithromycinLevofloxacin may increase the QTc-prolonging activities of Clarithromycin.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Levofloxacin.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Levofloxacin.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Levofloxacin.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Levofloxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Levofloxacin.Approved
ClofazimineThe serum concentration of Levofloxacin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Levofloxacin.Approved, Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Levofloxacin.Approved
ClonixinClonixin may increase the neuroexcitatory activities of Levofloxacin.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Levofloxacin.Approved, Nutraceutical
ClorindioneLevofloxacin may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe serum concentration of Levofloxacin can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Levofloxacin.Approved
CobicistatThe serum concentration of Levofloxacin can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Levofloxacin.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Levofloxacin.Approved
ColforsinThe serum concentration of Levofloxacin can be increased when it is combined with Colforsin.Experimental, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Levofloxacin.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Levofloxacin.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Levofloxacin.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Levofloxacin.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Levofloxacin.Approved
CrizotinibLevofloxacin may increase the QTc-prolonging activities of Crizotinib.Approved
CurcuminCurcumin may increase the neuroexcitatory activities of Levofloxacin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Levofloxacin.Approved, Investigational
CyclosporineThe serum concentration of Levofloxacin can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Levofloxacin.Experimental
D-LimoneneD-Limonene may increase the neuroexcitatory activities of Levofloxacin.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Levofloxacin.Approved
DabrafenibDabrafenib may increase the QTc-prolonging activities of Levofloxacin.Approved
DaclatasvirThe serum concentration of Levofloxacin can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Levofloxacin can be increased when it is combined with Dactinomycin.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Levofloxacin.Approved
DasatinibDasatinib may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
DaunorubicinThe serum concentration of Levofloxacin can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Levofloxacin.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Levofloxacin.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Levofloxacin.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Levofloxacin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Levofloxacin.Approved
DesloratadineThe serum concentration of Levofloxacin can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Levofloxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Levofloxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Levofloxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Levofloxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Levofloxacin.Vet Approved
DextromethorphanThe serum concentration of Levofloxacin can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Levofloxacin.Approved, Illicit, Vet Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Levofloxacin.Approved, Vet Approved
DicoumarolLevofloxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Levofloxacin.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Levofloxacin.Approved, Investigational
DifenpiramideDifenpiramide may increase the neuroexcitatory activities of Levofloxacin.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Levofloxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Levofloxacin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Levofloxacin.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Levofloxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Levofloxacin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Levofloxacin.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Levofloxacin.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Levofloxacin.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Levofloxacin.Experimental
DihydroergotamineThe serum concentration of Levofloxacin can be increased when it is combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Levofloxacin.Illicit
DiltiazemThe serum concentration of Levofloxacin can be increased when it is combined with Diltiazem.Approved
DiphenadioneLevofloxacin may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Levofloxacin.Approved
DipyridamoleThe serum concentration of Levofloxacin can be increased when it is combined with Dipyridamole.Approved
DisopyramideLevofloxacin may increase the hypoglycemic activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Levofloxacin.Approved, Investigational
DofetilideLevofloxacin may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Levofloxacin.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Levofloxacin.Approved, Investigational, Vet Approved
DoxazosinThe serum concentration of Levofloxacin can be increased when it is combined with Doxazosin.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Levofloxacin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Levofloxacin.Approved, Investigational
DoxorubicinThe serum concentration of Levofloxacin can be decreased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Levofloxacin can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Levofloxacin can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
DroxicamDroxicam may increase the neuroexcitatory activities of Levofloxacin.Approved
DulaglutideLevofloxacin may increase the hypoglycemic activities of Dulaglutide.Approved
DuvelisibDuvelisib may increase the neuroexcitatory activities of Levofloxacin.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Levofloxacin.Approved
E-6201E-6201 may increase the neuroexcitatory activities of Levofloxacin.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Levofloxacin.Approved
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Levofloxacin.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Levofloxacin.Approved, Investigational
EliglustatLevofloxacin may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinLevofloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilThe serum concentration of Levofloxacin can be increased when it is combined with Enalapril.Approved, Vet Approved
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Levofloxacin.Approved
EnzalutamideThe serum concentration of Levofloxacin can be increased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Levofloxacin.Approved, Investigational
EpirizoleEpirizole may increase the neuroexcitatory activities of Levofloxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Levofloxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Levofloxacin.Approved
ErgonovineThe serum concentration of Levofloxacin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Levofloxacin can be increased when it is combined with Ergotamine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Levofloxacin.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
EscitalopramLevofloxacin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Levofloxacin.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Levofloxacin can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Levofloxacin can be decreased when it is combined with Estriol.Approved, Investigational, Vet Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Levofloxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Levofloxacin.Approved
EtanerceptEtanercept may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
EthenzamideEthenzamide may increase the neuroexcitatory activities of Levofloxacin.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Levofloxacin.Approved
Ethyl biscoumacetateLevofloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
EtoposideThe serum concentration of Levofloxacin can be increased when it is combined with Etoposide.Approved
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
EtravirineThe serum concentration of Levofloxacin can be increased when it is combined with Etravirine.Approved
Evening primrose oilEvening primrose oil may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Levofloxacin.Approved
ExenatideLevofloxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
exisulindexisulind may increase the neuroexcitatory activities of Levofloxacin.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Levofloxacin.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Levofloxacin.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Levofloxacin.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Levofloxacin.Approved
FelbinacFelbinac may increase the neuroexcitatory activities of Levofloxacin.Experimental
FelodipineThe serum concentration of Levofloxacin can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may increase the neuroexcitatory activities of Levofloxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Levofloxacin.Approved
FentanylThe serum concentration of Levofloxacin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FentiazacFentiazac may increase the neuroexcitatory activities of Levofloxacin.Experimental
FeprazoneFeprazone may increase the neuroexcitatory activities of Levofloxacin.Experimental
Ferric CarboxymaltoseThe serum concentration of Levofloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric CitrateThe serum concentration of Levofloxacin can be decreased when it is combined with Ferric Citrate.Approved, Investigational
Ferric pyrophosphateThe serum concentration of Levofloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
Ferulic acidFerulic acid may increase the neuroexcitatory activities of Levofloxacin.Experimental
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Levofloxacin.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Levofloxacin.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Levofloxacin.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
FlecainideLevofloxacin may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FloctafenineFloctafenine may increase the neuroexcitatory activities of Levofloxacin.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Levofloxacin.Investigational
FluconazoleFluconazole may increase the QTc-prolonging activities of Levofloxacin.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Levofloxacin.Approved
FluindioneLevofloxacin may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Levofloxacin.Approved, Vet Approved
FlunixinFlunixin may increase the neuroexcitatory activities of Levofloxacin.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the neuroexcitatory activities of Levofloxacin.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Levofloxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Levofloxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Levofloxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Levofloxacin.Approved
FluoxetineThe serum concentration of Levofloxacin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Levofloxacin can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Levofloxacin can be increased when it is combined with Fluphenazine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Levofloxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Levofloxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Levofloxacin.Approved
FlurazepamThe serum concentration of Levofloxacin can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Levofloxacin.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Levofloxacin.Approved
FluvoxamineThe serum concentration of Levofloxacin can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Levofloxacin.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
FoscarnetFoscarnet may increase the QTc-prolonging activities of Levofloxacin.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Levofloxacin.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Levofloxacin.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Levofloxacin.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Levofloxacin.Approved
GemifloxacinLevofloxacin may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Levofloxacin can be increased when it is combined with Genistein.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Levofloxacin.Experimental
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Levofloxacin.Approved
GliclazideLevofloxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideLevofloxacin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideLevofloxacin may increase the hypoglycemic activities of Glipizide.Approved
GlyburideThe serum concentration of Levofloxacin can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Levofloxacin can be increased when it is combined with Glycerin.Approved, Investigational
GoserelinGoserelin may increase the QTc-prolonging activities of Levofloxacin.Approved
Gramicidin DThe serum concentration of Levofloxacin can be increased when it is combined with Gramicidin D.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Levofloxacin.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Levofloxacin.Investigational, Withdrawn
GuacetisalGuacetisal may increase the neuroexcitatory activities of Levofloxacin.Experimental
HaloperidolHaloperidol may increase the QTc-prolonging activities of Levofloxacin.Approved
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Levofloxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Levofloxacin.Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Levofloxacin.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Levofloxacin.Approved, Vet Approved
HydrotalciteHydrotalcite can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Levofloxacin.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
IbuprofenIbuprofen may increase the neuroexcitatory activities of Levofloxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Levofloxacin.Withdrawn
IbutilideLevofloxacin may increase the QTc-prolonging activities of Ibutilide.Approved
IcatibantIcatibant may increase the neuroexcitatory activities of Levofloxacin.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Levofloxacin.Approved
IloperidoneLevofloxacin may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Levofloxacin.Approved
Imidazole salicylateImidazole salicylate may increase the neuroexcitatory activities of Levofloxacin.Experimental
ImipramineImipramine may increase the QTc-prolonging activities of Levofloxacin.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Levofloxacin.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Levofloxacin.Approved
IndinavirThe serum concentration of Levofloxacin can be decreased when it is combined with Indinavir.Approved
IndobufenIndobufen may increase the neuroexcitatory activities of Levofloxacin.Investigational
IndomethacinIndomethacin may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Levofloxacin.Withdrawn
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Levofloxacin.Approved
Insulin AspartLevofloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirLevofloxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineLevofloxacin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineLevofloxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanLevofloxacin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproLevofloxacin may increase the hypoglycemic activities of Insulin Lispro.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Levofloxacin.Approved, Investigational
IronThe serum concentration of Levofloxacin can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Levofloxacin can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Levofloxacin can be decreased when it is combined with Iron saccharate.Approved
IsavuconazoniumThe serum concentration of Levofloxacin can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsofluraneIsoflurane may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
IsoxicamIsoxicam may increase the neuroexcitatory activities of Levofloxacin.Withdrawn
IsradipineIsradipine may increase the QTc-prolonging activities of Levofloxacin.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Levofloxacin.Investigational
ItraconazoleItraconazole may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Levofloxacin.Approved
IvacaftorThe serum concentration of Levofloxacin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Levofloxacin can be increased when it is combined with Ivermectin.Approved, Vet Approved
KebuzoneKebuzone may increase the neuroexcitatory activities of Levofloxacin.Experimental
KetamineThe serum concentration of Levofloxacin can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Levofloxacin.Approved
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
KetoprofenKetoprofen may increase the neuroexcitatory activities of Levofloxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Levofloxacin.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Levofloxacin.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Levofloxacin.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Levofloxacin.Experimental
LansoprazoleThe serum concentration of Levofloxacin can be increased when it is combined with Lansoprazole.Approved, Investigational
Lanthanum carbonateThe serum concentration of Levofloxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LapatinibLapatinib may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Levofloxacin.Approved
LeflunomideLeflunomide may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Levofloxacin.Approved
LenvatinibLevofloxacin may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Levofloxacin.Approved
LevothyroxineThe serum concentration of Levofloxacin can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Levofloxacin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Levofloxacin.Approved
LiothyronineThe serum concentration of Levofloxacin can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Levofloxacin can be decreased when it is combined with Liotrix.Approved
LiraglutideLevofloxacin may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilThe serum concentration of Levofloxacin can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may increase the neuroexcitatory activities of Levofloxacin.Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Levofloxacin.Approved, Investigational
LithiumLithium may increase the QTc-prolonging activities of Levofloxacin.Approved
LomitapideThe serum concentration of Levofloxacin can be increased when it is combined with Lomitapide.Approved
LonazolacLonazolac may increase the neuroexcitatory activities of Levofloxacin.Experimental
LoperamideThe serum concentration of Levofloxacin can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Levofloxacin can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Levofloxacin can be increased when it is combined with Loratadine.Approved
LornoxicamLornoxicam may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LosartanThe serum concentration of Levofloxacin can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Levofloxacin can be increased when it is combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LumacaftorThe serum concentration of Levofloxacin can be decreased when it is combined with Lumacaftor.Approved
LumefantrineLevofloxacin may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Levofloxacin.Illicit, Investigational, Withdrawn
MagaldrateMagaldrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateThe serum concentration of Levofloxacin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium SulfateThe serum concentration of Levofloxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Levofloxacin.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Levofloxacin.Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Levofloxacin.Investigational
MebendazoleThe serum concentration of Levofloxacin can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecaserminLevofloxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Levofloxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Levofloxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Levofloxacin.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Levofloxacin.Approved
Megestrol acetateThe serum concentration of Levofloxacin can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Levofloxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Levofloxacin.Approved, Vet Approved
MeprobamateThe serum concentration of Levofloxacin can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineMesalazine may increase the neuroexcitatory activities of Levofloxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Levofloxacin.Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Levofloxacin.Experimental
MetforminLevofloxacin may increase the hypoglycemic activities of Metformin.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Levofloxacin.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Levofloxacin.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Levofloxacin.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Levofloxacin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Levofloxacin.Approved, Vet Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Levofloxacin.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Levofloxacin.Experimental
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
MetoprololThe serum concentration of Levofloxacin can be increased when it is combined with Metoprolol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Levofloxacin.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Levofloxacin.Experimental
MibefradilThe serum concentration of Levofloxacin can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Levofloxacin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Levofloxacin can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
MiglitolLevofloxacin may increase the hypoglycemic activities of Miglitol.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Levofloxacin.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Levofloxacin.Approved
MitomycinThe serum concentration of Levofloxacin can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Levofloxacin can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MizoribineMizoribine may increase the neuroexcitatory activities of Levofloxacin.Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Levofloxacin.Approved
MofebutazoneMofebutazone may increase the neuroexcitatory activities of Levofloxacin.Experimental
MorphineThe serum concentration of Levofloxacin can be increased when it is combined with Morphine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Levofloxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Levofloxacin.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Levofloxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Levofloxacin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Levofloxacin.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Levofloxacin.Approved, Vet Approved
NaltrexoneThe serum concentration of Levofloxacin can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Levofloxacin.Approved, Vet Approved
NaringeninThe serum concentration of Levofloxacin can be increased when it is combined with Naringenin.Experimental
NateglinideLevofloxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Levofloxacin.Investigational
NefazodoneThe serum concentration of Levofloxacin can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirNelfinavir may increase the QTc-prolonging activities of Levofloxacin.Approved
NeostigmineThe serum concentration of Levofloxacin can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacNepafenac may increase the neuroexcitatory activities of Levofloxacin.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Levofloxacin.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Levofloxacin.Approved, Investigational
NifedipineThe serum concentration of Levofloxacin can be decreased when it is combined with Nifedipine.Approved
NifenazoneNifenazone may increase the neuroexcitatory activities of Levofloxacin.Experimental
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Levofloxacin.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Levofloxacin.Approved, Investigational
NimesulideNimesulide may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational, Withdrawn
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Levofloxacin.Approved
NisoldipineThe serum concentration of Levofloxacin can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Levofloxacin can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Levofloxacin can be increased when it is combined with Nitrendipine.Approved, Investigational
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Levofloxacin.Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Levofloxacin.Approved
NorethisteroneThe serum concentration of Levofloxacin can be decreased when it is combined with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Levofloxacin.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Levofloxacin.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Levofloxacin.Investigational
OfloxacinLevofloxacin may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Levofloxacin.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Levofloxacin.Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Levofloxacin.Approved
OlopatadineOlopatadine may increase the neuroexcitatory activities of Levofloxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Levofloxacin.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Levofloxacin.Approved
OmeprazoleThe serum concentration of Levofloxacin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Levofloxacin.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Levofloxacin.Vet Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Levofloxacin.Approved
OuabainOuabain may decrease the cardiotoxic activities of Levofloxacin.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Levofloxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Levofloxacin.Approved, Withdrawn
OxytocinOxytocin may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
P-NitrophenolThe serum concentration of Levofloxacin can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Levofloxacin.Approved, Vet Approved
PaliperidoneLevofloxacin may increase the QTc-prolonging activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Levofloxacin can be increased when it is combined with Palmitic Acid.Approved, Experimental
PanobinostatLevofloxacin may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Levofloxacin can be increased when it is combined with Pantoprazole.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Levofloxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Levofloxacin.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
ParthenolideParthenolide may increase the neuroexcitatory activities of Levofloxacin.Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Levofloxacin.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Levofloxacin.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Levofloxacin.Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Levofloxacin.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Levofloxacin.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Levofloxacin can be increased when it is combined with Perindopril.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Levofloxacin.Experimental
PhenindioneLevofloxacin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe serum concentration of Levofloxacin can be decreased when it is combined with Phenobarbital.Approved
PhenprocoumonLevofloxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Levofloxacin.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Levofloxacin.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Levofloxacin.Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Levofloxacin.Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
PimozideThe serum concentration of Levofloxacin can be increased when it is combined with Pimozide.Approved
PioglitazoneLevofloxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
PirprofenPirprofen may increase the neuroexcitatory activities of Levofloxacin.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Levofloxacin.Approved
Platelet Activating FactorThe serum concentration of Levofloxacin can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Levofloxacin.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Levofloxacin.Approved
PosaconazolePosaconazole may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational, Vet Approved
PramlintideLevofloxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PranoprofenPranoprofen may increase the neuroexcitatory activities of Levofloxacin.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Levofloxacin.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Levofloxacin.Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Levofloxacin.Approved
PrazosinThe serum concentration of Levofloxacin can be increased when it is combined with Prazosin.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Levofloxacin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Levofloxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Levofloxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Levofloxacin.Experimental, Investigational
PrimaquinePrimaquine may increase the QTc-prolonging activities of Levofloxacin.Approved
ProbenecidThe serum concentration of Levofloxacin can be increased when it is combined with Probenecid.Approved
ProcainamideLevofloxacin may increase the QTc-prolonging activities of Procainamide.Approved
ProgesteroneThe serum concentration of Levofloxacin can be decreased when it is combined with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the neuroexcitatory activities of Levofloxacin.Experimental
PromazinePromazine may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Levofloxacin.Approved
PropacetamolPropacetamol may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
PropafenoneLevofloxacin may increase the QTc-prolonging activities of Propafenone.Approved
PropofolPropofol may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Levofloxacin.Approved, Investigational
PropyphenazonePropyphenazone may increase the neuroexcitatory activities of Levofloxacin.Experimental
ProquazoneProquazone may increase the neuroexcitatory activities of Levofloxacin.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Levofloxacin.Experimental
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Levofloxacin.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Levofloxacin.Approved
PTC299PTC299 may increase the neuroexcitatory activities of Levofloxacin.Investigational
QuercetinThe serum concentration of Levofloxacin can be increased when it is combined with Quercetin.Experimental, Investigational
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Levofloxacin.Approved
QuinacrineThe serum concentration of Levofloxacin can be increased when it is combined with Quinacrine.Approved, Investigational
QuinaprilThe serum concentration of Levofloxacin can be decreased when it is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Levofloxacin can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Levofloxacin can be increased when it is combined with Quinine.Approved
RanitidineThe serum concentration of Levofloxacin can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Levofloxacin.Approved, Investigational
ReboxetineThe serum concentration of Levofloxacin can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Levofloxacin can be increased when it is combined with Regorafenib.Approved
RepaglinideLevofloxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ReserpineThe serum concentration of Levofloxacin can be decreased when it is combined with Reserpine.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Levofloxacin.Approved, Experimental, Investigational
RifampicinThe serum concentration of Levofloxacin can be decreased when it is combined with Rifampicin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Levofloxacin.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Levofloxacin.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Levofloxacin.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Levofloxacin.Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Levofloxacin.Investigational, Withdrawn
RolapitantThe serum concentration of Levofloxacin can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Levofloxacin.Approved, Investigational
RosiglitazoneLevofloxacin may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Levofloxacin.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
SalicylamideSalicylamide may increase the neuroexcitatory activities of Levofloxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Levofloxacin.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Levofloxacin.Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Levofloxacin.Approved
SaquinavirLevofloxacin may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SaxagliptinLevofloxacin may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe serum concentration of Levofloxacin can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Levofloxacin can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Levofloxacin.Approved
SemapimodSemapimod may increase the neuroexcitatory activities of Levofloxacin.Investigational
SeratrodastSeratrodast may increase the neuroexcitatory activities of Levofloxacin.Approved
SerrapeptaseSerrapeptase may increase the neuroexcitatory activities of Levofloxacin.Investigational
SertralineSertraline may increase the QTc-prolonging activities of Levofloxacin.Approved
SevelamerSevelamer can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Levofloxacin.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Levofloxacin.Approved
SimvastatinThe serum concentration of Levofloxacin can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Levofloxacin can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Levofloxacin.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Levofloxacin.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Levofloxacin.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
SotalolLevofloxacin may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Levofloxacin.Approved, Investigational
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Levofloxacin.Experimental
SpironolactoneThe serum concentration of Levofloxacin can be increased when it is combined with Spironolactone.Approved
SRT501SRT501 may increase the neuroexcitatory activities of Levofloxacin.Investigational
St. John's WortThe serum concentration of Levofloxacin can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StaurosporineThe serum concentration of Levofloxacin can be increased when it is combined with Staurosporine.Experimental
StreptozocinThe serum concentration of Levofloxacin can be decreased when it is combined with Streptozocin.Approved
Strontium ranelateThe serum concentration of Levofloxacin can be decreased when it is combined with Strontium ranelate.Approved
SucralfateThe serum concentration of Levofloxacin can be decreased when it is combined with Sucralfate.Approved
SulfadiazineLevofloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Levofloxacin.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Levofloxacin.Approved
SulfinpyrazoneThe serum concentration of Levofloxacin can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Levofloxacin.Approved
SumatriptanThe serum concentration of Levofloxacin can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Levofloxacin.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the neuroexcitatory activities of Levofloxacin.Experimental
TacrineThe serum concentration of Levofloxacin can be increased when it is combined with Tacrine.Investigational, Withdrawn
TacrolimusLevofloxacin may increase the QTc-prolonging activities of Tacrolimus.Approved, Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Levofloxacin.Approved
TarenflurbilTarenflurbil may increase the neuroexcitatory activities of Levofloxacin.Investigational
Taurocholic AcidThe serum concentration of Levofloxacin can be increased when it is combined with Taurocholic Acid.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Levofloxacin.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Levofloxacin.Approved, Withdrawn
TelavancinLevofloxacin may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Levofloxacin.Approved
TelmisartanThe serum concentration of Levofloxacin can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Levofloxacin.Approved
TenidapTenidap may increase the neuroexcitatory activities of Levofloxacin.Experimental
TenoxicamTenoxicam may increase the neuroexcitatory activities of Levofloxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Levofloxacin.Vet Approved
TerazosinThe serum concentration of Levofloxacin can be increased when it is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Levofloxacin.Approved
TerfenadineThe serum concentration of Levofloxacin can be increased when it is combined with Terfenadine.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Levofloxacin.Experimental
TeriflunomideThe serum concentration of Levofloxacin can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Levofloxacin can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Levofloxacin can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineLevofloxacin may increase the QTc-prolonging activities of Tetrabenazine.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Levofloxacin.Approved
ThioridazineLevofloxacin may increase the QTc-prolonging activities of Thioridazine.Approved, Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Levofloxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Levofloxacin.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Levofloxacin.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Levofloxacin.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Levofloxacin.Investigational
TioclomarolLevofloxacin may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Levofloxacin.Approved
TizanidineTizanidine may increase the QTc-prolonging activities of Levofloxacin.Approved
TolazamideLevofloxacin may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideLevofloxacin may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Levofloxacin.Approved
TolmetinTolmetin may increase the neuroexcitatory activities of Levofloxacin.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Levofloxacin.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Levofloxacin.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Levofloxacin.Approved, Investigational
TranilastTranilast may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Levofloxacin.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Levofloxacin.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Levofloxacin.Approved, Vet Approved
TribenosideTribenoside may increase the neuroexcitatory activities of Levofloxacin.Experimental
TrifluoperazineThe serum concentration of Levofloxacin can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Levofloxacin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Levofloxacin.Approved
TriptolideTriptolide may increase the neuroexcitatory activities of Levofloxacin.Investigational
TriptorelinTriptorelin may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
TroleandomycinThe serum concentration of Levofloxacin can be increased when it is combined with Troleandomycin.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Levofloxacin.Approved, Experimental
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Levofloxacin.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Levofloxacin.Approved
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Levofloxacin.Investigational, Withdrawn
VandetanibLevofloxacin may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Levofloxacin.Approved
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Levofloxacin.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Levofloxacin.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Levofloxacin.Approved
VemurafenibLevofloxacin may increase the QTc-prolonging activities of Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Levofloxacin.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Levofloxacin.Approved
VerapamilThe serum concentration of Levofloxacin can be decreased when it is combined with Verapamil.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Levofloxacin.Approved
VinblastineThe serum concentration of Levofloxacin can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Levofloxacin.Approved, Investigational
VincristineThe serum concentration of Levofloxacin can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Levofloxacin can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Levofloxacin.Approved
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Levofloxacin.Approved
WarfarinLevofloxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Levofloxacin.Approved
ZileutonZileuton may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Levofloxacin can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneLevofloxacin may increase the QTc-prolonging activities of Ziprasidone.Approved
ZomepiracZomepirac may increase the neuroexcitatory activities of Levofloxacin.Withdrawn
ZuclopenthixolLevofloxacin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Take with water, drink lliberally. Taking this product with orange juice can result in reduced quinolone plasma levels.

References

Synthesis Reference

Valerie Niddam-Hildesheim, "Preparation of levofloxacin and forms thereof." U.S. Patent US20030130507, issued July 10, 2003.

US20030130507
General References
Not Available
External Links
Human Metabolome Database
HMDB01929
KEGG Compound
C07660
PubChem Compound
149096
PubChem Substance
46505134
ChemSpider
131410
BindingDB
50366826
ChEBI
63598
ChEMBL
CHEMBL33
Therapeutic Targets Database
DAP000160
PharmGKB
PA450214
HET
LFX
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Levofloxacin
ATC Codes
J01RA05 — Levofloxacin and ornidazoleA02BD10 — Lansoprazole, amoxicillin and levofloxacinS01AE05 — LevofloxacinJ01MA12 — Levofloxacin
AHFS Codes
  • 08:12.18 — Quinolones
PDB Entries
3k9f / 3rae / 4juo / 4z2d / 5btg / 5bti / 5eix
FDA label
Download (139 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingPreventionComplications of Surgical Procedures1
0RecruitingTreatmentOsteomyelitis1
1CompletedNot AvailableCystic Fibrosis (CF)1
1CompletedDiagnosticLung Function / Sarcoidosis, Pulmonary1
1CompletedHealth Services ResearchHealthy Volunteers1
1CompletedPreventionChronic Obstructive Pulmonary Disease (COPD)1
1CompletedTreatmentCystic Fibrosis (CF)1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentHealthy Volunteers / The Focus of This Study Was to Assess the Effect of Food Following a Single Oral Dose of Levofloxacin Solution1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
1CompletedTreatmentRenal Diseases1
1TerminatedNot AvailableEscherichia Coli Infections1
1TerminatedTreatmentOveractive Bladder / Overactive Urinary Bladder1
1, 2CompletedTreatmentTB Multi-drug Resistant1
1, 2RecruitingTreatmentTuberculous Meningitis1
1, 2Unknown StatusTreatmentCorneal Diseases / Hypermetropia / Myopia / Pterygium1
2CompletedNot AvailableHealthy Volunteers1
2CompletedTreatmentAcute Pyelonephritis / Complicated Urinary Tract Infections1
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
2CompletedTreatmentCommunity Acquired Pneumonia (CAP)1
2CompletedTreatmentCommunity-Acquired Bacterial Pneumonia (CABP)1
2CompletedTreatmentCystic Fibrosis (CF)1
2CompletedTreatmentDiabetic Foot Ulcers (DFU)2
2CompletedTreatmentFoot Ulcer, Diabetic1
2CompletedTreatmentTuberculosis, Multidrug Resistant1
2Not Yet RecruitingTreatmentAcute Appendicitis1
2RecruitingSupportive CareStem Cell Transplant Complications1
2RecruitingTreatmentChronic Bacterial Prostatitis1
2RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
2RecruitingTreatmentSarcoidosis; Antimycobacterial Therapy1
2RecruitingTreatmentTuberculosis, Multidrug Resistant1
2TerminatedTreatmentCancers / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentCommunity Acquired Pneumonia (CAP)1
2TerminatedTreatmentInfected Spacers / Prosthetic Joint Infections of Hip / Prosthetic Joint Infections of Knee1
2, 3CompletedTreatmentAcute Exacerbation of Chronic Obstructive Pulmonary Disease1
2, 3CompletedTreatmentBronchitis / Chronic Bronchitis1
2, 3CompletedTreatmentCellulitis / Skin Diseases, Infectious1
2, 3CompletedTreatmentPneumonia1
2, 3RecruitingTreatmentExtensively-drug Resistant Tuberculosis / Tuberculosis / Tuberculosis, Multidrug Resistant1
2, 3Unknown StatusPreventionAllogeneic Stem Cell Transplantation / Malignancies1
3Active Not RecruitingSupportive CareAcute Leukemias of Ambiguous Lineage / Diarrhea / Infections, Bacterial / Infections, Fungal / Musculoskeletal Complications / Neutropenias / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3Active Not RecruitingTreatmentComplicated Urinary Tract Infections1
3Active Not RecruitingTreatmentComplicated Urinary Tract Infections (cUTIs)1
3CompletedNot AvailableProstatic Hyperplasia / Prostatitis1
3CompletedPreventionCataract operation1
3CompletedSupportive CareBrain and Central Nervous System Tumors / Cancer, Breast / Cancer, Ovarian / Extragonadal Germ Cell Tumor / Infection NOS / Lung Cancers / Malignant Lymphomas / Small Intestine Cancer / Testicular germ cell tumour / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedTreatmentAcute Lower Urinary Tract Infection1
3CompletedTreatmentAcute Pyelonephritis / Complicated Urinary Tract Infections1
3CompletedTreatmentAcute Pyelonephritis / Urinary Tract Infection Complicated1
3CompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)2
3CompletedTreatmentBacteriuria / Infections, Bacterial / Urinary Tract Infections (UTIs) / Urologic Diseases1
3CompletedTreatmentBacteriuria / Neurogenic Bladder Dysfunction / Pyelonephritis / Urinary Tract Infections (UTIs) / Urologic Diseases1
3CompletedTreatmentChronic Bronchitis2
3CompletedTreatmentCommunity Acquired Pneumonia (CAP)1
3CompletedTreatmentCommunity-Acquired Infections / Cross Infection / Pneumonia, Bacterial1
3CompletedTreatmentComplicated Urinary Tract Infections / Pyelonephritis1
3CompletedTreatmentCystic Fibrosis (CF)2
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
3CompletedTreatmentMaxillary Sinusitis2
3CompletedTreatmentMaxillary Sinusitis / Sinusitis1
3CompletedTreatmentOtitis Media (OM)2
3CompletedTreatmentPelvic Inflammatory Disease (PID)1
3CompletedTreatmentPneumonia6
3CompletedTreatmentProstatitis3
3CompletedTreatmentPyelonephritis / Urinary Tract Infections (UTIs)1
3CompletedTreatmentSinusitis1
3CompletedTreatmentSkin Diseases, Bacterial1
3CompletedTreatmentSkin Diseases, Infectious1
3CompletedTreatmentHospital-acquired bacterial pneumonia1
3Not Yet RecruitingPreventionPrevention1
3Not Yet RecruitingTreatmentChronic Rhinosinusitis (Diagnosis)1
3RecruitingPreventionAtrioventricular block complete / Chronic Systolic Heart Failure / Sick Sinus Syndrome / Syncope1
3RecruitingTreatmentChronic Rhinosinusitis1
3RecruitingTreatmentHelicobacter-associated Gastritis1
3RecruitingTreatmentIndigestion1
3RecruitingTreatmentInfective Endocarditis1
3RecruitingTreatmentKeratitis; Infectious Disease (Manifestation)1
3RecruitingTreatmentMDR-TB1
3RecruitingTreatmentTuberculosis, Multidrug Resistant1
3TerminatedTreatmentInfection NOS1
3TerminatedTreatmentInfection in Solid Organ Transplant Recipients / Latent Tuberculosis Infection (LTI)1
3TerminatedTreatmentStaphylococcus1
3TerminatedTreatmentTuberculous infections1
3Unknown StatusSupportive CareFever, Sweats, and Hot Flashes / Infection NOS / Leukemias / Malignant Lymphomas / Neutropenias / Unspecified Adult Solid Tumor, Protocol Specific1
3Unknown StatusTreatmentAcute Exacerbation of Chronic Bronchitis (AECB)1
3WithdrawnTreatmentTuberculosis Multi Drug Resistant Active1
4Active Not RecruitingTreatmentHelicobacter Pylori Gastrointestinal Tract Infection1
4CompletedNot AvailableBacteremia / Endocarditis / Sepsis / Staphylococcus Aureus1
4CompletedNot AvailableHelicobacter Infections1
4CompletedBasic ScienceCataracts1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedPreventionDisease Due to BK Polyomavirus / Kidney Transplant Infection1
4CompletedTreatmentAcute Bacterial Sinusitis (ABS)1
4CompletedTreatmentAcute Exacerbation of Chronic Obstructive Pulmonary Disease2
4CompletedTreatmentBK Viremia1
4CompletedTreatmentBMI >30 kg/m2 / Critical Illness1
4CompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
4CompletedTreatmentCataract Extraction1
4CompletedTreatmentCataracts1
4CompletedTreatmentCataracts / Dry Eye Syndromes1
4CompletedTreatmentCommunity Acquired Pneumonia (CAP)1
4CompletedTreatmentCommunity Acquired Pneumonia (CAP) / Intensive Care Unit Syndrome1
4CompletedTreatmentCommunity-acquired / Pneumonia, Bacterial1
4CompletedTreatmentCure Rate of Helicobacter Pylori Infection1
4CompletedTreatmentFevers / Urinary Tract Infections (UTIs)1
4CompletedTreatmentFunctional Dyspepsia / Peptic Ulcers1
4CompletedTreatmentHelicobacter Infections1
4CompletedTreatmentPneumonia1
4CompletedTreatmentTuberculosis, Pulmonary1
4Not Yet RecruitingTreatmentAntimicrobial Susceptibility Testing / Triple Therapy1
4Not Yet RecruitingTreatmentHelicobacter Pylori Gastrointestinal Tract Infection1
4RecruitingPreventionProstate Cancer1
4RecruitingTreatmentAntimicrobial Susceptibility Testing / Bacterial Infection Due to Helicobacter Pylori (H. Pylori)1
4RecruitingTreatmentBacillus Calmette-Guerin (BCG) Cystitis / Intra-vesical Instillation / Non-Muscle-invasive Bladder Cancer (NMIBC)1
4RecruitingTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
4RecruitingTreatmentCholangitis1
4RecruitingTreatmentCommunity Acquired Pneumonia (CAP)2
4RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4RecruitingTreatmentMycoplasma Pneumoniae Pneumonia1
4RecruitingTreatmentTuberculosis, Pulmonary1
4RecruitingTreatmentUrinary Tract Infections (UTIs)1
4TerminatedBasic ScienceTransplantation, Corneal1
4TerminatedTreatmentAcute Uncomplicated Pyelonephritis1
4TerminatedTreatmentAppendicitis1
4TerminatedTreatmentComplicated Urinary Infection1
4TerminatedTreatmentPneumonia, Pneumococcal1
4Unknown StatusTreatmentCommunity Acquired Pneumonia (CAP)1
4Unknown StatusTreatmentEradication Rate for Helicobacter1
4Unknown StatusTreatmentUrinary Tract Infections (UTIs)1
Not AvailableActive Not RecruitingOtherAnti-Bacterial Agents / Microbiota1
Not AvailableCompletedNot AvailableAcute maxillary sinusitis caused by M. catarrhalis1
Not AvailableCompletedNot AvailableEnd Stage Renal Disease (ESRD) / Infection NOS1
Not AvailableCompletedPreventionEndophthalmitis1
Not AvailableCompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
Not AvailableCompletedTreatmentGastritis1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
Not AvailableCompletedTreatmentOsteoarticular Infections1
Not AvailableEnrolling by InvitationTreatmentAcute Appendicitis1
Not AvailableNot Yet RecruitingTreatmentAntibiotics / Infection NOS / Percutaneous Nephrolithotomy / Sepsis1
Not AvailableRecruitingTreatmentAcute Appendicitis1
Not AvailableRecruitingTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)2
Not AvailableRecruitingTreatmentBronchiectasis1
Not AvailableTerminatedTreatmentAcute Watery Diarrhea / Dysentery/Febrile Diarrhea1
Not AvailableUnknown StatusNot AvailableAsymptomatic Infections / Bacteriuria / Transplantation Infection / Urinary Tract Infections (UTIs)1
Not AvailableUnknown StatusTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
SolutionOphthalmic15 mg/mL
SolutionIntravenous25 mg
SolutionIntravenous5 mg
InjectionIntravenous25 mg/mL
InjectionIntravenous5 mg/mL
Injection, solutionIntravenous25 mg/mL
Injection, solutionIntravenous250 mg/50mL
Injection, solutionIntravenous5 mg/mL
Injection, solutionIntravenous500 mg/100mL
Injection, solutionIntravenous750 mg/150mL
Injection, solution, concentrateIntravenous25 mg/mL
Injection, solution, concentrateIntravenous500 mg/20mL
Injection, solution, concentrateIntravenous750 mg/30mL
SolutionOral25 mg/mL
Solution / dropsOphthalmic5 mg/mL
Solution / dropsTopical5 mg/mL
TabletOral250 mg/1
TabletOral500 mg/1
TabletOral750 mg/1
Tablet, film coatedOral250 mg/1
Tablet, film coatedOral500 mg/1
Tablet, film coatedOral750 mg/1
TabletOral250 mg
TabletOral500 mg
SolutionRespiratory (inhalation)240 mg
SolutionOphthalmic5 mg/mL
TabletOral750 mg
Prices
Unit descriptionCostUnit
Iquix 1.5% Solution 5ml Bottle81.68USD bottle
Levofloxacin hemihydr 100% powder42.69USD g
Levaquin 750 mg tablet28.06USD each
Levaquin 750 mg leva-pak tablet27.51USD tablet
Levaquin 500 mg tablet16.57USD tablet
Iquix 1.5% eye drops15.71USD ml
Levaquin 250 mg tablet13.71USD tablet
Quixin 0.5% eye drops12.21USD ml
Quixin 0.5% Solution11.4USD ml
Levaquin i.v. 25 mg/ml vial1.94USD ml
Levaquin 500 mg/100 ml d5w0.44USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5053407No1993-12-202010-12-20Us
US6806256Yes2002-08-262022-08-26Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityInsolubleNot Available
logP2.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.44 mg/mLALOGPS
logP-0.02ALOGPS
logP0.65ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)5.45ChemAxon
pKa (Strongest Basic)6.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area73.32 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity94.94 m3·mol-1ChemAxon
Polarizability36.69 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
MS/MS Spectrum - Quattro_QQQ 10V, N/ALC-MS/MSsplash10-00gm-1315975420-b0c4e6cdef799fda69b4
MS/MS Spectrum - Quattro_QQQ 25V, N/ALC-MS/MSsplash10-0abc-3459425420-e8a4ecd2f8aea93fa660
MS/MS Spectrum - Quattro_QQQ 40V, N/ALC-MS/MSsplash10-0h9p-3513893500-1d5c8069419fa2c37ebb
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0009000000-63138044688fa3ab0792
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-02t9-0019000000-265eec70cbb77077fbfa
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-1290000000-3ff2c315dfac97ded8c5
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0axr-1980000000-e31472e2487627c51cea
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0adl-1930000000-3cd445f16118ecf3f610
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0049000000-3cbab894a4b0d1165e7d
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-2492000000-62b30ac9148b06791816
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Fluoroquinolones / N-arylpiperazines / Haloquinolines / Hydroquinolones / Aminoquinolines and derivatives / Benzoxazines / Hydroquinolines / Pyridinecarboxylic acids / Dialkylarylamines / N-methylpiperazines
show 15 more
Substituents
Quinoline-3-carboxylic acid / Fluoroquinolone / N-arylpiperazine / Aminoquinoline / Haloquinoline / Dihydroquinolone / Benzoxazine / Dihydroquinoline / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives
show 34 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
quinolone antibiotic, fluoroquinolone antibiotic, ofloxacin (CHEBI:63598)

Targets

Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, inc...
Gene Name
gyrA
Uniprot ID
P43700
Uniprot Name
DNA gyrase subunit A
Molecular Weight
97817.145 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Schmitz FJ, Hofmann B, Hansen B, Scheuring S, Luckefahr M, Klootwijk M, Verhoef J, Fluit A, Heinz HP, Kohrer K, Jones ME: Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 1998 Apr;41(4):481-4. [PubMed:9598779]
  4. Brisse S, Milatovic D, Fluit AC, Verhoef J, Martin N, Scheuring S, Kohrer K, Schmitz FJ: Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins. Antimicrob Agents Chemother. 1999 Aug;43(8):2051-5. [PubMed:10428935]
  5. Messina C, Cafiso V, Campanile F, Santagati M, Stefani S: Rapid method for detection of gyrA and grlA mutations in unrelated strains of Staphylococci susceptible and resistant to levofloxacin. New Microbiol. 2001 Oct;24(4):347-53. [PubMed:11718372]
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name
parC
Uniprot ID
P43702
Uniprot Name
DNA topoisomerase 4 subunit A
Molecular Weight
83366.24 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Zheng X, Johnson C, Lu Y, Yanagihara R, Hollingshead S, Crain M, Benjamin W Jr, Waites KB: Clinical isolates of Streptococcus pneumoniae resistant to levofloxacin contain mutations in both gyrA and parC genes. Int J Antimicrob Agents. 2001 Oct;18(4):373-8. [PubMed:11691571]
  4. Schafer J, Hovde LB, Simonson D, Rotschafer JC: In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant. Diagn Microbiol Infect Dis. 2008 Feb;60(2):155-61. Epub 2007 Oct 29. [PubMed:17910998]
  5. Deryke CA, Du X, Nicolau DP: Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. J Antimicrob Chemother. 2006 Sep;58(3):601-9. Epub 2006 Jul 19. [PubMed:16857688]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Ubiquitin binding
Specific Function
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segr...
Gene Name
TOP2A
Uniprot ID
P11388
Uniprot Name
DNA topoisomerase 2-alpha
Molecular Weight
174383.88 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Bellon A, Perez-Garcia G, Coverdale JH, Chacko RC: Seizures associated with levofloxacin: case presentation and literature review. Eur J Clin Pharmacol. 2009 Oct;65(10):959-62. doi: 10.1007/s00228-009-0717-5. Epub 2009 Aug 26. [PubMed:19707748]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Ito T, Yano I, Tanaka K, Inui KI: Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther. 1997 Aug;282(2):955-60. [PubMed:9262363]
  2. Yamaguchi H, Yano I, Hashimoto Y, Inui KI: Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2. J Pharmacol Exp Ther. 2000 Oct;295(1):360-6. [PubMed:10992002]
  3. Yamaguchi H, Yano I, Saito H, Inui K: Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats. Pharm Res. 2004 Feb;21(2):330-8. [PubMed:15032316]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Uwai Y, Okuda M, Takami K, Hashimoto Y, Inui K: Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Lett. 1998 Nov 6;438(3):321-4. [PubMed:9827570]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Urakami Y, Akazawa M, Saito H, Okuda M, Inui K: cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol. 2002 Jul;13(7):1703-10. [PubMed:12089365]
  2. Okuda M, Urakami Y, Saito H, Inui K: Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochim Biophys Acta. 1999 Mar 4;1417(2):224-31. [PubMed:10082798]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without...
Gene Name
SLC22A4
Uniprot ID
Q9H015
Uniprot Name
Solute carrier family 22 member 4
Molecular Weight
62154.48 Da
References
  1. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. [PubMed:10215651]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2017 21:49